Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Authors

Sarah A. Bird^{1, 2}, Graham H. Jackson³, Charlotte Pawlyn^{1, 2, *,}

¹The Institute of Cancer Research, London

²The Royal Marsden NHS Foundation Trust, London

³Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, England

^*Corresponding author. Postal address: The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP. Tel.: 02087224000. Email: charlotte.pawlyn@icr.ac.uk

DOI

10.2991/chi.d.200502.001How to use a DOI?

Keywords

Myeloma; Maintenance therapy; Post-ASCT

Abstract

Multiple myeloma, the second most common hematological malignancy worldwide, has demonstrated dramatic improvements in outcome in the last decade. In newly diagnosed patients, induction chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care. After ASCT, the majority of patients experience disease remission but, despite recent therapeutic developments, most will eventually relapse. In this review we consider clinical aspects of maintenance therapies that can be used post-ASCT to prolong remission duration. We discuss the evidence for the effectiveness of each of these drugs as a maintenance therapy, alongside other benefits and drawbacks to their use, for example, route of administration and potential toxicities. We discuss questions which remain unanswered around the optimal use of currently available maintenance therapies and review newer agents being considered for use as maintenance such as emerging immunotherapies.

Copyright

© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - Sarah A. Bird
AU  - Graham H. Jackson
AU  - Charlotte Pawlyn
PY  - 2020
DA  - 2020/05/20
TI  - Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
JO  - Clinical Hematology International
SP  - 59
EP  - 68
VL  - 2
IS  - 2
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.200502.001
DO  - 10.2991/chi.d.200502.001
ID  - Bird2020
ER  -